Page 12 - hypertension_newsletter8

REFLECTIONS
Hypertension
Hypertension Global Newsletter #8 2025

Effects of glucagon-like peptide-1 receptor agonists on blood pressure in Hypertension

overweight or obese patients: a meta-analysis of randomized controlled trials.
Wong HJ, et al. J Hypertens. 2025 Feb 1;43(2):290-300.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications with proven efficacy in treating type 2 diabetes mellitus
(T2DM) and have been increasingly used as a weight loss medication. Hypertension is a common comorbidity of diseases like
T2DM and obesity, and the frequent copresentation of multiple cardiovascular morbidities carries significant consequences.
Despite present evidence suggesting GLP-1 RAs have proven efficacy in improving metabolic derangements in either patients
with T2DM or in patients with obesity, there is a lack of evidence for the effects of GLP-1 RAs on reducing BP in patients with
both T2DM and obesity.

This meta-analysis aimed to summarise current insights into the utilisation of GLP-1 RAs for BP reduction in obese and
overweight patients, with or without diabetes, to facilitate drug selection, administration protocols, target population, and
guideline development. A total of 30 randomised control trials published up to February 2024 were included in this meta-
analysis. This constituted a pooled population of 37,072 patients, all of whom were either overweight or obese, with or without
diabetes mellitus treated with any available GLP-1 RA (liraglutide, semaglutide, and exenatide). The data extracted consisted of
baseline parameters, the GLP-1 RA used, including drug name, dosage, frequency, and route of administration, and SBP and
DBP changes.

TABLE OF CONTENTS